High Grade Glioma Clinical Trials

31 studies are recruiting for high grade glioma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Dabrafenib and/or Trametinib Rollover Study

   This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by…

   Stage

   Phase 4

   Ages

   18 to 100

   Site

   Novartis Investigative Site, Toronto, Ontario

   Locations

   34 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT03340506 on ClinicalTrials.gov

2. A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors

   This is an open label, Phase 1b safety, dose-finding, brain tumor delivery, and pharmacokinetics study of intranasal NEO100 in patients with pediatric-type diffuse high grade gliomas. Patients will receive IN NEO100 that will follow a dose titration design, followed by a standard dose escalation de…

   Stage

   Phase 1

   Ages

   5 to 18

   Site

   Children's Hospital Orange County (CHOC), Orange, California

   Run by

   Neonc Technologies, Inc.

   See if you can join NCT06357377 on ClinicalTrials.gov

3. Targeted Pediatric High-Grade Glioma Therapy

   The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligible to participate in a subsequent treatment-based clinical …

   Stage

   Not phased

   Ages

   1 to 39

   Site

   Children's National Medical Center, Washington D.C., District of Columbia

   Locations

   22 in total

   Run by

   Nationwide Children's Hospital

   See if you can join NCT05839379 on ClinicalTrials.gov

4. Study of Olutasidenib and Temozolomide in HGG

   The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozol…

   Stage

   Phase 2

   Ages

   12 to 39

   Site

   University of Miami Hospital and Clinics, Miami, Florida

   Locations

   20 in total

   Run by

   Rigel Pharmaceuticals

   See if you can join NCT06161974 on ClinicalTrials.gov

5. PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

   This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB). PEP-CMV is a v…

   Stage

   Phase 2

   Ages

   3 to 39

   Site

   Children's Hospital Colorado, Aurora, Colorado

   Locations

   13 in total

   Run by

   Nationwide Children's Hospital

   See if you can join NCT05096481 on ClinicalTrials.gov

6. Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma

   This feasibility study will assess the clinical potential of a new imaging approach to detect viable high grade glioma (HGG) in pediatric and adult patients after standard of care radiation therapy (RT) with or without concurrent temozolomide (TMZ). Study participants will undergo simultaneous posi…

   Stage

   EARLY_Phase 1

   Ages

   10 to 89

   Site

   UAB, Birmingham, Alabama

   Locations

   2 in total

   Run by

   University of Alabama at Birmingham

   See if you can join NCT05632562 on ClinicalTrials.gov

7. MRI in High-Grade Glioma Patients Undergoing Chemoradiation

   The purpose of this research study is to see if investigators can predict how brain functioning changes after radiation treatment based on PET scans and blood tests. Most participants experience at least mild decreases in their memory or attention after radiation therapy. Investigators hope that PE…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina

   Run by

   Wake Forest University Health Sciences

   See if you can join NCT05212272 on ClinicalTrials.gov

8. Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression

   The purpose of this study is to test the safety and feasibility of recording brain activity within and around high-grade glioma tumors at the time of surgery. A small biopsy will be taken at the sites of the recordings.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio

   Run by

   Case Comprehensive Cancer Center

   See if you can join NCT05565118 on ClinicalTrials.gov

9. C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)

   In this study, there are two treatment groups called Cohort 1 and Cohort 2. Cohort 1 is for patients with diffuse midline glioma, diffuse intrinsic pontine glioma, medulloblastoma, or another rare high-grade glioma that expresses GD2. Cohort 2 is for patients with a type of cancer called progressiv…

   Stage

   Phase 1

   Ages

   1 to 25

   Site

   Texas Children's Hospital, Houston, Texas

   Run by

   Baylor College of Medicine

   See if you can join NCT04099797 on ClinicalTrials.gov

10. Atovaquone Combined With Radiation in Children With Malignant Brain Tumors

    The goal of this interventional study is to Assess the safety and tolerability of atovaquone in combination with standard radiation therapy (RT) for the treatment of pediatric patients with newly diagnosed pediatric high-grade glioma/diffuse midline glioma/diffuse intrinsic pontine glioma (pHGG/DMG…

    Stage

    Phase 1

    Ages

    2 to 25

    Site

    Arthur M Blank Hospital, Atlanta, Georgia

    Locations

    2 in total

    Run by

    Emory University

    See if you can join NCT06624371 on ClinicalTrials.gov

11. Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

    Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatment and is often fatal. Researchers want to know if a study drug (LMP744) can kill glioblastoma tumor cells. Objective: To test LMP744 in peop…

    Stage

    Phase 1

    Ages

    18 to 99

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Institute of Neurological Disorders and Stroke (NINDS)

    See if you can join NCT07416188 on ClinicalTrials.gov

12. Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

    This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS) tumors and meningiomas that demonstrate uptake on DOTATATE PET. The drug will be given intravenously once every 8 weeks for a total of up …

    Stage

    Phase 1

    Ages

    4 to 39

    Site

    Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

    Locations

    4 in total

    Run by

    Nationwide Children's Hospital

    See if you can join NCT05278208 on ClinicalTrials.gov

13. MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

    Pediatric gliomas harboring BRAF-alterations, commonly BRAFV600 mutation or KIAA1549-BRAF fusion, are currently treated with either chemotherapy or mitogen activated protein kinase (MAPK) inhibitors, such as, dabrafenib and/or trametinib. Unfortunately, some BRAF-altered gliomas can progress or hav…

    Stage

    Phase 1

    Ages

    1 to 26

    Site

    Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois

    Locations

    3 in total

    Run by

    Ann & Robert H Lurie Children's Hospital of Chicago

    See if you can join NCT06712875 on ClinicalTrials.gov

14. Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

    High-grade gliomas (HGGs) are among the most aggressive and treatment-resistant brain tumors. Immunotherapy with checkpoint inhibitors like nivolumab has shown promise, but its efficacy remains variable and poorly understood in this patient population. This clinical trial investigates a novel imagi…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Vanderbilt University Medical Center, Nashville, Tennessee

    Run by

    Eben Rosenthal

    See if you can join NCT07210632 on ClinicalTrials.gov

15. Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

    The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1. It will also evaluate the safety of lorlatinib when given with chemotherapy or after radiation therapy.

    Stage

    EARLY_Phase 1

    Ages

    1 to 21

    Site

    Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

    Locations

    18 in total

    Run by

    Nationwide Children's Hospital

    See if you can join NCT06333899 on ClinicalTrials.gov

16. A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)

    The primary objective will be to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in (Stratum 1) adult patients with newly diagnosed GBM (MGMT low level or unmethylated in adults only) and (Stratum 2) in pediatric patients wi…

    Stage

    Phase 1

    Ages

    4 and older

    Site

    Children's National Hospital, Washington D.C., District of Columbia

    Locations

    2 in total

    Run by

    University of Florida

    See if you can join NCT04573140 on ClinicalTrials.gov

17. STARLITE for Unresectable High-Grade Gliomas

    The purpose of this study is to determine whether newly diagnosed high-grade glioma(s) that cannot be removed surgically change as a result of the study treatment; and to identify and evaluate the potential side effects (good and bad) of the study treatment in patients with newly diagnosed high-gra…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Miami, Miami, Florida

    Run by

    University of Miami

    See if you can join NCT06428045 on ClinicalTrials.gov

18. Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma

    This single center, single arm, open-label, phase 2 study will assess the safety and efficacy of a pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multifome (GBM) patients. The objective of the Phase 2 study is to demonstrate that…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Lenox Hill Brain Tumor Center, New York, New York

    Run by

    Northwell Health

    See if you can join NCT05954858 on ClinicalTrials.gov

19. Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)

    This single center, single arm, open-label, phase I study will assess the safety of laparoscopically harvested autologous omentum, implanted into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Lenox Hill Brain Tumor Center, New York, New York

    Run by

    Northwell Health

    See if you can join NCT05979064 on ClinicalTrials.gov

20. Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

    The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle, PI3K/mTOR) that these drugs target or 2) ribociclib …

    Stage

    Phase 2

    Ages

    1 to 39

    Site

    Children's National Medical Center, Washington D.C., District of Columbia

    Locations

    20 in total

    Run by

    Nationwide Children's Hospital

    See if you can join NCT05843253 on ClinicalTrials.gov

21. DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

    The purpose of this study is to determine if the investigational products, DB107-RRV and DB107-FC, as a combination treatment will shrink high-grade glioma (HGG) in patients with recurrent/progressive, resectable or unresectable disease and increase the time that disease is controlled.

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    University of Miami Hospital, Miami, Florida

    Run by

    Ashish Shah

    See if you can join NCT06264388 on ClinicalTrials.gov

22. Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

    This clinical trial tests how well entrectinib works to treat patients less than 3 years of age with NTRK 1/2/3 or ROS1 fused, high grade glioma or other central nervous system (CNS) tumors.

    Stage

    Phase 2

    Ages

    Up to 3

    Site

    St. Jude Children's Research Hospital, Memphis, Tennessee

    Locations

    6 in total

    Run by

    St. Jude Children's Research Hospital

    See if you can join NCT06528691 on ClinicalTrials.gov

23. Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.

    This is a phase I, open-Label, single/multiple dose, dose-escalation study to evaluate the safety, tolerability and antitumor activity of anti-B7-H3 CAR-T cell injection (TX103) in subjects with recurrent or progressive Grade 4 Glioma.The study also plan to explore the Maximum Tolerated Dose (MTD) …

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    Mayo Clinic in Arizona, Phoenix, Arizona

    Locations

    4 in total

    Run by

    Tcelltech Inc.

    See if you can join NCT06482905 on ClinicalTrials.gov

24. A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

    This is a pilot study that will evaluate disease status in children that have been newly diagnosed high-grade glioma with TRK fusion. The evaluation will occur after 2 cycles of the medication (Larotrectinib) have been given. The study will also evaluate the safety of larotrectinib when given with …

    Stage

    EARLY_Phase 1

    Ages

    Up to 21

    Site

    Children's Hospital Colorado, Aurora, Colorado

    Locations

    21 in total

    Run by

    Nationwide Children's Hospital

    See if you can join NCT04655404 on ClinicalTrials.gov

25. DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

    This is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in newly diagnosed High Grade Glioma (HGG) patients. The study is designed to evaluate whether treatment with DB107-RRV in combination with DB107-F…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Southern California, Los Angeles, California

    Locations

    5 in total

    Run by

    University of California, San Francisco

    See if you can join NCT06504381 on ClinicalTrials.gov